Contribution of cost to treatment nonadherence in the US breast cancer survivors: a population-based analysis

[1] AlOmeir OA-O(2020)Adherence to adjuvant endocrine therapy among breast cancer survivors: a systematic review and meta-synthesis of the qualitative literature using grounded theory Support Care Cancer 28 5075-5084

[2] Patel NA-O(2015)Breast cancer survivorship: where are we today? Adv Exp Med Biol 862 1-8

[3] Donyai PA-O(2015)A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer Breast Cancer Res Treat 151 27-40

[4] Ganz PA(2016)Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis JAMA Oncol 2 1477-1486

[5] Goodwin PJ(2010)American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer J Clin Oncol 28 3784-3796

[6] Diaby V(1998)Tamoxifen for early breast cancer: an overview of the randomised trials. Early breast cancer trialists' collaborative group Lancet 351 1451-1467

[7] Tawk R(2012)Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review Breast Cancer Res Treat 134 459-478

[8] Sanogo V(2017)Association between out-of-pocket costs, race/ethnicity, and adjuvant endocrine therapy adherence among medicare patients with breast cancer J Clin Oncol 35 86-95

[9] Xiao H(2018)The association between out-of-pocket costs and adherence to adjuvant endocrine therapy among newly diagnosed breast cancer patients Am J Clin Oncol 41 708-715

[10] Montero AJ(2019)The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer Cancer 125 374-381

[1] AlOmeir OA-O(2020)Adherence to adjuvant endocrine therapy among breast cancer survivors: a systematic review and meta-synthesis of the qualitative literature using grounded theory Support Care Cancer 28 5075-5084

[2] Patel NA-O(2015)Breast cancer survivorship: where are we today? Adv Exp Med Biol 862 1-8

[3] Donyai PA-O(2015)A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer Breast Cancer Res Treat 151 27-40

[4] Ganz PA(2016)Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis JAMA Oncol 2 1477-1486

[5] Goodwin PJ(2010)American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer J Clin Oncol 28 3784-3796

[6] Diaby V(1998)Tamoxifen for early breast cancer: an overview of the randomised trials. Early breast cancer trialists' collaborative group Lancet 351 1451-1467

[7] Tawk R(2012)Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review Breast Cancer Res Treat 134 459-478

[8] Sanogo V(2017)Association between out-of-pocket costs, race/ethnicity, and adjuvant endocrine therapy adherence among medicare patients with breast cancer J Clin Oncol 35 86-95

[9] Xiao H(2018)The association between out-of-pocket costs and adherence to adjuvant endocrine therapy among newly diagnosed breast cancer patients Am J Clin Oncol 41 708-715

[10] Montero AJ(2019)The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer Cancer 125 374-381